InVivo Therapeutics Holdings Corporation
NVIVNASDAQHealthcare
$0.32
$-0.17(-34.28%)
Market Cap$995918
P/E Ratio—
52W High$2.4
52W Low$0.22
InVivo Therapeutics Holdings Corporation (NVIV) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NVIV · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.00B | $0.00B | $0.01B | $0.00B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Operating Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.02B |
| Net Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.05B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.62 | $-7.47 | $-32.80 | $-912.63 | $-3725.45 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more InVivo Therapeutics Holdings Corporation data
About InVivo Therapeutics Holdings Corporation (NVIV) Income Statement
InVivo Therapeutics Holdings Corporation (NVIV) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, NVIV reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
NVIV · 4 questionsInVivo Therapeutics Holdings Corporation (NVIV) reported revenue of $0.00B for 2022, down —% year-over-year.
NVIV revenueNVIV salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09